多重PCR快速检测弥漫性大B细胞淋巴瘤患者骨髓BCL2/IGH与BCL6/IGH融合基因的临床意义  

Clinical Significance of Rapid Detecting Bone Marrow BCL2/IGH and BCL6/IGH Fusion Genes in Patients with Diffuse Large B Cell Lymphoma by Multiplex PCR

作　　者：郭玥潞[1] 董丽丽[1] 高丽[1] 徐媛媛[1] 丁一[1] 王莉莉[1] 靖彧[1] 薄剑[1] 周敏航[1] 曹婷婷[1] 于力[1] 

机构地区：[1]中国人民解放军总医院血液科,北京100853

出　　处：《中国实验血液学杂志》2012年第6期1370-1373,共4页Journal of Experimental Hematology

基　　金：国家自然科学基金重点项目(编号90919044;81170518);军队高新技术基金(编号2010gxjs091);首都医学发展科学基金(编号2007-2040)

摘　　要：弥漫性大B细胞淋巴瘤(DLBCL)是最常见的侵袭性非霍奇金淋巴瘤,其临床表现、分子生物学特点都有显著的异质性。本研究旨在探讨多重PCR技术在DLBCL患者骨髓BCL2/IGH及BCL6/IGH等融合基因检测中的临床意义。利用多重巢式PCR技术对80例初治DLBCL患者的骨髓标本进行BCL2/IGH及BCL6/IGH融合基因检测。结果表明,80例患者骨髓标本中携带目的融合基因共12例,阳性率为15%;其中BCL2-IGH阳性患者为6例,BCL6-IGH阳性患者为6例。DLBCL患者携带不同的融合基因具有不同的临床特点。结论:运用多重PCR方法对DLBCL患者进行分子生物学检测具有快速、准确的优点。但需进一步深入研究改善方法,使之对融合基因能做定量或半定量分析,这对于DLBCL患者的诊断、协助分期、预后评估、微小残留病变的估测,指导临床治疗DLBCL有重要意义。Diffuse large B cell lymphoma （DLBCL） is the most common aggressive non-Hodgkin＇s lymphoma （NHL）, characterized by great heterogeneity in clinical manifestations and molecular genetics. This study was aimed to explore the clinical significance of applying multiplex PCR to detect BCL2/IGH and BCL6/IGH fusion genes in DLBCL. Multiplex PCR was used to detect bone marrow samples from 80 cases of DLBCL. The results showed that 12 patients （ 15% ） carded BCL2/1GH or BCL6/IGH fusion genes, BCL2/IGH was found in 6 patients （7.5%）, and BCL6/IGH in another 6 patients （7.5 % ）. The patients with different molecular markers displayed-different clinical features and out- comes. It is concluded that multiple PCR is rapid and accurate method to identify gene abnormalities in DLBCL, but further studing a quantitative or semi-quantitative assay for the expression of fusion genes is needed.

关 键 词：弥漫性大B细胞淋巴瘤 多重PCR BCL2 IGH融合基因 BCL6 IGH融合基因 

分 类 号：R733.1[医药卫生—肿瘤]